FIELD: medicine, therapy.
SUBSTANCE: group of inventions is intended for the treatment of tumors in patients suffering from them. Compounds of formula (I) or (II) are provided, wherein the meanings of the various substituents are defined herein. In another embodiment, a pharmaceutical composition containing the said compounds is provided. Also a method of treating a tumor in a patient using the said compounds is provided, which can be delivered orally for systemic exposure or intratumorally. Also the use of the said compounds for the treatment of a tumor in a patient is provided. Antitumor therapy using these compounds may further include the administration of an effective dose of a drug that targets the checkpoint of the immune response.
EFFECT: group of inventions provides new compounds of formula (I) or (II) having agonistic bioactivity with respect to interferon gene stimulator (STING), which can be used in the treatment of tumors in patients suffering from them.
9 cl, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BICYCLIC AGONISTS OF STING INTERFERON GENE STIMULATOR | 2020 |
|
RU2813691C2 |
| MACROCYCLIC WIDE-RANGE ANTIBIOTICS | 2018 |
|
RU2779477C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| MACROCYCLIC ANTIBIOTICS OF WIDE SPECTRUM OF ACTION | 2016 |
|
RU2761476C2 |
| MACROCYCLIC ANTIBIOTICS OF WIDE RANGE OF ACTIONS | 2016 |
|
RU2766543C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
| BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | 2019 |
|
RU2806274C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| COMPOUNDS 6,7-DIHYDRO-5H-PYRAZOLO[5,1-B][1,3]OXAZINE-2-CARBOXAMIDE | 2017 |
|
RU2719599C2 |
| PYRAZOLOPYRIDINE DERIVATIVES AS KINASE 1β-ADRENERGIC RECEPTOR INHIBITORS | 2006 |
|
RU2415855C2 |
